Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE),  American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA). 

RSS icon
Society of cardiovascular computed tomography (SCCT) President Kavitha Chinnaiyan, MD, FACC, MSCCT, a cardiologist and professor of medicine at Oakland University William Beaumont School of Medicine in Royal Oak, with is part of Corewell Health, explains some of the key trends in coronary computed tomography angiography (CCTA) and how this is being translated into educational programming at the SCCT 2026 annual scientific meeting (ASM). #SCCT2026

SCCT President: Key trends in cardiac CT

As CCTA sees rapid adoption across cardiology, SCCT is working to address the education required to sustain the expansion.

cardiologist viewing heart data

TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision

When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.

cardiologists evaluating the human heart to provide a treatment strategy

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

HRS President, Mina Chung, MD, FHRS, staff cardiologist and Professor of Medicine in the Section of Pacing and Electrophysiology, Heart & Vascular Institute, Cleveland Clinic. Explains HRS accomplishments in the past year in terms of advocacy efforts and policy concerns impacting EP. #HRS2026 #EPeeps

Heart Rhythm 2026: Electrophysiologist Mina Chung discusses CPR, PFA and much more

Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.

Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 

The Society for Cardiovascular Angiography and Interventions (SCAI) is entering a new chapter as Dawn Abbott, MD, MSCAI, who assumeed the presidency this week with a focus on strengthening the future of interventional cardiology through workforce development, expanded training pathways and continued efforts to broaden inclusion in the specialty. #SCAI2026 #SCAI26

New SCAI President Dawn Abbott outlines workforce training and inclusion priorities

SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.

Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B

Fewer stents, positive outcomes: Sirolimus-eluting balloons a safe alternative during PCI

Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.

GLP-1 receptor agonists (GLP-1-RAs) have become the wonder drug not only of weight loss, but also for improving cardiovascular health in a growing number of positive cardiovascular trials. The latest study of more than 13,000 patients presented at Heart Rhythm 2026 this week showed the GLP-1 reduce atrial fibrillation (AFib) and survival, even after accounting for the drug’s impact on weight loss.

Multiple GLP-1 drugs linked to lower AFib risk

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 

Displaying 25 - 32 of 1535
Design by Adaptive Theme